Literature DB >> 35227905

Trends in pharmacologic treatment of chronic idiopathic urticaria from 2016 to 2020.

Lily Li1, Joan E Landon2, Seoyoung C Kim3.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 35227905      PMCID： PMC9058201          DOI： 10.1016/j.anai.2022.02.006

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN： 1081-1206            Impact factor:   6.248


× No keyword cloud information.
  10 in total

1.  Metrics for covariate balance in cohort studies of causal effects.

Authors:  Jessica M Franklin; Jeremy A Rassen; Diana Ackermann; Dorothee B Bartels; Sebastian Schneeweiss
Journal:  Stat Med       Date:  2013-12-09       Impact factor: 2.373

2.  Real-World Characteristics and Treatment Patterns in Patients with Urticaria Initiating Omalizumab in the United States.

Authors:  Xuehua Ke; Abhishek Kavati; Debra Wertz; Qing Huang; Liya Wang; Vincent J Willey; Judith J Stephenson; Benjamin Ortiz; Brandee Paknis; Jonathan A Bernstein; Lisa A Beck
Journal:  J Manag Care Spec Pharm       Date:  2017-12-19

Review 3.  The diagnosis and management of acute and chronic urticaria: 2014 update.

Authors:  Jonathan A Bernstein; David M Lang; David A Khan; Timothy Craig; David Dreyfus; Fred Hsieh; Javed Sheikh; David Weldon; Bruce Zuraw; David I Bernstein; Joann Blessing-Moore; Linda Cox; Richard A Nicklas; John Oppenheimer; Jay M Portnoy; Christopher R Randolph; Diane E Schuller; Sheldon L Spector; Stephen A Tilles; Dana Wallace
Journal:  J Allergy Clin Immunol       Date:  2014-05       Impact factor: 10.793

4.  Trends in Omalizumab Utilization for Asthma: Evidence of Suboptimal Patient Selection.

Authors:  Molly M Jeffery; Nilay D Shah; Pinar Karaca-Mandic; Joseph S Ross; Matthew A Rank
Journal:  J Allergy Clin Immunol Pract       Date:  2017-09-22

5.  Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.

Authors:  Marcus Maurer; Karin Rosén; Hsin-Ju Hsieh; Sarbjit Saini; Clive Grattan; Ana Gimenéz-Arnau; Sunil Agarwal; Ramona Doyle; Janice Canvin; Allen Kaplan; Thomas Casale
Journal:  N Engl J Med       Date:  2013-02-24       Impact factor: 91.245

Review 6.  Role of Biologics in Asthma.

Authors:  Mary Clare McGregor; James G Krings; Parameswaran Nair; Mario Castro
Journal:  Am J Respir Crit Care Med       Date:  2019-02-15       Impact factor: 21.405

7.  The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria.

Authors:  Torsten Zuberbier; Amir Hamzah Abdul Latiff; Mohamed Abuzakouk; Susan Aquilina; Riccardo Asero; Diane Baker; Barbara Ballmer-Weber; Christine Bangert; Moshe Ben-Shoshan; Jonathan A Bernstein; Carsten Bindslev-Jensen; Knut Brockow; Zenon Brzoza; Herberto Jose Chong Neto; Martin K Church; Paulo R Criado; Inna V Danilycheva; Corinna Dressler; Luis Felipe Ensina; Luz Fonacier; Matthew Gaskins; Krisztian Gáspár; Aslı Gelincik; Ana Giménez-Arnau; Kiran Godse; Margarida Gonçalo; Clive Grattan; Martine Grosber; Eckard Hamelmann; Jacques Hébert; Michihiro Hide; Allen Kaplan; Alexander Kapp; Aharon Kessel; Emek Kocatürk; Kanokvalai Kulthanan; Désirée Larenas-Linnemann; Antti Lauerma; Tabi A Leslie; Markus Magerl; Michael Makris; Raisa Y Meshkova; Martin Metz; Daniel Micallef; Charlotte G Mortz; Alexander Nast; Hanneke Oude-Elberink; Ruby Pawankar; Paolo D Pigatto; Hector Ratti Sisa; María Isabel Rojo Gutiérrez; Sarbjit S Saini; Peter Schmid-Grendelmeier; Bulent E Sekerel; Frank Siebenhaar; Hanna Siiskonen; Angele Soria; Petra Staubach-Renz; Luca Stingeni; Gordon Sussman; Andrea Szegedi; Simon Francis Thomsen; Zahava Vadasz; Christian Vestergaard; Bettina Wedi; Zuotao Zhao; Marcus Maurer
Journal:  Allergy       Date:  2021-10-20       Impact factor: 13.146

8.  Prevalence of chronic urticaria in children and adults across the globe: Systematic review with meta-analysis.

Authors:  Julia Fricke; Gabriela Ávila; Theresa Keller; Karsten Weller; Susanne Lau; Marcus Maurer; Torsten Zuberbier; Thomas Keil
Journal:  Allergy       Date:  2019-10-11       Impact factor: 13.146

9.  Real-world use of omalizumab in patients with chronic idiopathic/spontaneous urticaria in the United States.

Authors:  Jacqueline Eghrari-Sabet; Ellen Sher; Abhishek Kavati; Dominic Pilon; Maryia Zhdanava; Maria-Magdalena Balp; Patrick Lefebvre; Benjamin Ortiz; Jonathan A Bernstein
Journal:  Allergy Asthma Proc       Date:  2018-02-19       Impact factor: 2.587

10.  Positive impact of omalizumab on angioedema and quality of life in patients with refractory chronic idiopathic/spontaneous urticaria: analyses according to the presence or absence of angioedema.

Authors:  M Maurer; H Sofen; B Ortiz; F Kianifard; S Gabriel; J A Bernstein
Journal:  J Eur Acad Dermatol Venereol       Date:  2017-01-17       Impact factor: 6.166
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.